Also found in: Medical, Wikipedia.
Related to rivastigmine: Memantine, Rivastigmine tartrate


A drug, C14H22N2O2, that inhibits the action of cholinesterase and is used to treat dementia in people with Alzheimer's disease and Parkinson's disease.

[riva-, of unknown origin + (physo)stigmine.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


n rivastigmina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
It included 15 participants treated with rivastigmine or placebo.
M2 EQUITYBITES-January 15, 2019-Amneal wins US FDA approval for Rivastigmine Transdermal System
Global Banking News-January 15, 2019-Amneal wins US FDA approval for Rivastigmine Transdermal System
M2 PHARMA-January 15, 2019-Amneal wins US FDA approval for Rivastigmine Transdermal System
launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' (NVS) Exelon Patch.
and EU into emerging markets: a rivastigmine transdermal patch to treat Alzheimer's disease and fentanyl and buprenorphine transdermal patches for pain relief.
The researchers looked at evidence from 142 clinical trials of four common cognitive enhancers--donepezil, rivastigmine (Exelon[R]), galantamine (Razedyne[R]) and memantine (Namenda[R]).
Rivastigmine hydrogen tartrate (RHT) was approved by the US FDA in 2000 for the treatment of mild-to-moderate dementia of either Alzheimer's type or related to Parkinson's disease [1].
The team compared the safety and effectiveness of any combination of donepezil, rivastigmine, galantamine or memantine in treating moderate to severe Alzheimer's dementia.
Some recently published studies [5, 6] suggested some benefic properties of Rivastigmine on this NPS symptom too, in complete accordance with the results obtained by Devos et al.
According to Luye, the acquired business is one of the largest independent TDS manufacturers in Europe, with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone spaces under several successfully commercialised and hard-to-make formulations such as Rivastigmine, Buprenorphine, Fentanyl and fertility control patches.